NABI BIOPHARMACEUTICALS : OXGN

drenan

02 mai 2011 •21:49

go go go

Profil supprimé

02 mai 2011 •22:03

joli trade.

drenan

02 mai 2011 •22:14

mais c part pas mal, c vrai ;-)

drenan

06 mai 2011 •15:58

fois ; je viens de doubler à 1.73

drenan

06 mai 2011 •16:02

celle là ! ;-)

drenan

06 mai 2011 •23:39

à 3.5 ...

Profil supprimé

07 mai 2011 •00:42

bien ouéj !

drenan

11 mai 2011 •20:20

de l'année

Profil supprimé

11 mai 2011 •22:02

mais j'ai tjs été trop en avance ou trop en retard avec les biopharmas ...

byscotte

18 mai 2011 •14:21

OXiGENE annonce données cliniques de fait les études et FALCON être présentée à l'ASCO

FAIT Présentation orale des données finales de première instance du cancer anaplasique thyroïde Nommé «Best of ASCO" Programme

South San Francisco, en Californie, le 18 mai 2011 (GLOBE NEWSWIRE) -

OXiGENE, Inc (Nasdaq: OXGN), un stade clinique, société biopharmaceutique qui développe de nouvelles thérapies pour traiter les cancers et les maladies des yeux, a annoncé aujourd'hui que les données de ses essais cliniques de ZYBRESTAT ™ en combinaison avec la chimiothérapie chez les patients avec cancer de la thyroïde anaplasique (ATC ) et cancer non à petites cellules (CBNPC) sera présenté lors de la prochaine American Society of Clinical Oncology réunion annuelle à Chicago, Illinois le 3-7 Juin 2011.

OXiGENE a également annoncé que la présentation FAIT orale a été choisie pour être inclus dans le meilleur des ASCO ® programme, qui aura lieu peu après la réunion annuelle de l'ASCO. Le Best of ASCO est une initiative éducative qui condense les faits saillants de l'assemblée annuelle de l'ASCO dans un programme de deux jours et est destiné à accroître l'accès global à la science de pointe. Les résumés ont été sélectionnés selon des critères spécifiques et ne donnent que la recherche est pertinente et significative en oncologie d'aujourd'hui. En plus des deux meilleures intérieur des réunions de l'ASCO de Miami et Seattle, il y aura aussi environ dix-huit International Best of ASCO réunions et divers forfaits ASCO-licence.

FACT (Fosbretabulin en Cancer anaplasique de la thyroïde) Détails Présentation:

Titre de la présentation orale:

Une étude randomisée de phase II / III de l'essai d'une tumeur vasculaire trométhamine agent d'interruption fosbretabulin (CA4P) avec du carboplatine (C) et le paclitaxel (P) dans les cancers de la thyroïde anaplasique (ATC):
analyse de survie final de l'essai FACT

Présentateur: Julie Un Sosa, MD, École de médecine de l'Université Yale

Titre de la session: la tête et du cou

Date: Lundi 6 Juin, 2011

Durée de la session: 15h00-6h00 HAC

Lieu: S406 McCormick Place

FALCON (Fosbretabulin en oncologie du poumon avancé) Détails de l'affiche:

Titre de l'affiche:

Une étude randomisée de phase 2 de l'essai d'un agent de dislocation vasculaire (VDA) trométhamine fosbretabulin (CA4P) avec du carboplatine (C), le paclitaxel (P), le bevacizumab (B) à l'étape 3B / 4 non squameux cancer bronchique non à petites cellules (CBNPC) :
Analyse de la sécurité et de l'activité de l'essai FALCON

Garon B. Edward, MD, UCLA School of Medicine: Présentateur

Séance d'affiches général, la voie du cancer du poumon

Conseil d'affiche Résumé # 7559, # 34G

Date: Samedi 4 Juin, 2011

Durée de la session: 14h00-6h00 HAC

Hall McCormick Place A: Emplacement

Profil supprimé

18 mai 2011 •15:18

comme tu le sais, les résus des sctés qui seront prèsentes à l'AsCO dèbut juin sont sous embargo ; et c'est aujourd'hui que tout va être dèballé ! MIAM !

en somme : c’était prévu - d'ou aussi le Up des derniers jours ; seule inconnue: la teneur des résus..

tu devrais donc voir de sacrés écarts ce jour sur certaines biotechs ; TANT MIEUX, J'AI 8 Lignes de biotechs prèsentes à l' ASCO :-) et avec un Nasdaq vert ça devrait aider hi hi hi

byscotte

02 juin 2011 •05:51

http://www.sec.gov/Archives/edgar/data/908259/000095012311055799/b86815e424b5.ht m

byscotte

03 juin 2011 •19:51

Rien trouvé pour ma part...............

byscotte

03 juin 2011 •19:57

ASCO: OXGN a deux présentations de son agent anti-cancer Zybrestat à la réunion annuelle de l'American Society of Clinical Oncology, qui se tiendra ce week-end à Chicago.

Oxigène est prévue pour présenter les données d'une étude de Zybrestat dans le traitement du cancer du poumon samedi. Données d'une étude du médicament dans le traitement de la tête et du cou doit être présenté lundi.

byscotte

04 juin 2011 •21:09

OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer





SOUTH SAN FRANCISCO, Calif., June 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a stratified randomized, controlled Phase 2 study of ZYBRESTAT™ (fosbretabulin tromethamine, or CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The data were presented in a poster by Edward Garon, M.D., Assistant Professor of Medicine at the University of California, Los Angeles and primary investigator in the study.

An updated analysis conducted approximately 11 months after the enrollment of the last patient in June 2010 showed that the combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT Arm) was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. In addition, a pre-specified subgroup analysis showed meaningful improvements in median time to progression for patients with poor performance status (ECOG Performance Status 1). While the median time to progression for the overall patient population was similar in both arms of the study, 8.6 months for the ZYBRESTAT arm compared with 9.0 months on the control arm, an analysis of the patient strata showed that patients with poor performance status who received ZYBRESTAT in addition to bevacizumab and chemotherapy achieved a median time to progression of 9.8 months compared with only 3.8 months for patients in this same subgroup on the control arm of the study with a hazard ratio (95% CI) of 0.51 (0.23, 1.16).

These data were presented in a poster titled, "Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy of the FALCON Trial," by Dr. Garon.

"The FALCON results show evidence of activity with an increased response rate in patients who were treated with the combination of ZYBRESTAT, bevacizumab and chemotherapy. Non-small cell lung cancer patients with a poorer performance status also had a clinically meaningful increase in time to progression in patients. These results are highly encouraging," said Dr. Garon. "The suggestion that this combination may be especially beneficial in a sicker patient population should be explored in a larger trial to delineate the potential of targeting more advanced patient populations with the combined effects of a vascular disrupting agent, anti-angiogenic and chemotoxic therapies."

"With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of ZYBRESTAT," said Peter Langecker, M.D., Chief Executive Officer at OXiGENE. "In addition, this study provides data in non-small cell lung cancer suggesting that ZYBRESTAT may benefit patients with more advanced stages of disease, such as patients with ECOG 1 status. We believe that designing a development plan based on targeting this subgroup of patients could represent a sensible and achievable clinical strategy and we look forward to discussing further development of ZYBRESTAT with potential pharmaceutical partners."

FALCON is a randomized, controlled study investigating the addition of ZYBRESTAT (fosbretabulin tromethamine, or CA4P) to standard therapy (carboplatin, paclitaxel, and bevacizumab, or C/P/Bev) in patients with Stage IIIb or IV predominantly non-squamous NSCLC. Randomization was stratified by ECOG status and prior therapies. A total of 60 patients were treated with 29 in the standard therapy arm and 31 in the ZYBRESTAT + standard therapy arm (safety population). The treatment arms were well balanced except for a greater number of males in the CA4P arm. Disease was predominately Stage IV in both arms. Of the 60 patients treated, 29 were ECOG 1 status, with 16 ECOG 1 patients in the ZYBRESTAT arm and 13 ECOG 1 patients in the control arm. Patients received CA4P plus standard therapy, or standard therapy alone, every 21 days for up to 6 cycles (treatment phase). Patients without disease progression after 6 cycles could continue to receive bevacizumab with or without CA4P (depending on treatment arm) until disease progression (maintenance phase).

Key data points from the FALCON trial are as follows.

Progression-free survival (PFS)

PFS determined by RECIST criteria.
Median PFS was 8.6 months in the ZYBRESTAT arm versus 9.0 months in the standard therapy arm (HR with 95% CI: 1.05 (0.56, 1.98)).
Median PFS in patients with ECOG 0 status was 7.0 months in the ZYBRESTAT arm versus 11.5 months in the standard therapy arm (HR with 95% CI: 2.38 (1.00, 5.69)).
Median PFS in patients with ECOG 1 status was 9.8 months in the ZYBRESTAT arm versus 3.8 months in the standard therapy arm (HR with 95% CI: 0.51 (0.23, 1.16)).
Tumor response

Partial Response (PR) was 56% in the ZYBRESTAT arm and 36% in the standard therapy arm.
Tolerability

The addition of ZYBRESTAT to standard therapy appeared to be well tolerated.
Safety profiles were similar with ZYBRESTAT+ C/P/Bev and C/P/Bev.
Grade 3 hypertension was more frequent in the ZYBRESTAT arm and manageable with use of amlodipine prophylaxis or other anti-HTN medications following protocol management guidelines.
Grade 1-4 neutropenia was more frequent in the ZYBRESTAT arm, but there was no difference in dose reductions between the two treatment arms.
3 patients experienced transient and reversible cardiac ischemia that resolved within 24-72 hours.
The addition of ZYBRESTAT to C/P/Bev:
Slightly increased QTc prolongation (mostly Grade 1 or 2). 3 patients (1 in CA4P arm and 2 in C/P/Bev) had Grade 3 QTc prolongation.
Did not increase selected bevacizumab-associated safety events such as arterial thrombotic events, proteinuria, or bleeding.
Did not adversely affect renal or hepatic function.
A copy of the poster "Randomized Phase 2 Trial of a Vascular Disrupting Agent (VDA) Fosbretabulin Tromethamine (CA4P) with Carboplatin, Paclitaxel and Bevacizumab in Stage IIIB/IV Non-Squamous Non Small Cell Lung Cancer (NSCLC): Analyses of Safety and Efficacy of the FALCON Trial" is available on OXiGENE's website at www.oxigene.com.

About ZYBRESTAT (fosbretabulin tromethamine)

ZYBRESTAT is being evaluated in studies of patients with non-squamous non-small cell lung cancer, anaplastic thyroid cancer, platinum-sensitive ovarian cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4969

Safe Harbor Statement

byscotte

08 juin 2011 •12:22

Once again, the shorts made the same mistake by betting against the OXGN shareholder. With nearly 40% of the company owned by insiders, what are they thinking? The penny flippers, that sold for profit, are most certainly buying back at a discount courtesy of the short sellers. And the astute longs holding for the $25+ to $250+ levels, of course added more shares on the good news and again now... courtesy of the discount brought on by short sellers. The question now becomes, how long does this group offer the discount? The longer the discount is out there, the more shares the astute longs like myself will continue to accumulate.

The shorts lost this war a long time ago. Now it comes down to damage control for them as they gracefully try to cover. However, nothing they,ve done thus far has been graceful and they continue to set themselves up for even further damage. The next few weeks should be fun to watch. I think there biggest mistake was not letting OXGN fly over $10 on news. That way new margin buyers would have entered over $5 and at $10 they may have been able to book some profits to offset their losses. At these levels, the shorts are only putting band aids on their fatal wounds.

Posté par Harold Goldmann ( yahoo ) +++ sur la valeur

byscotte

22 juin 2011 •13:14

Exhibit Index
99.1 Letter dated June 21, 2011



EXHIBIT 99.1

Dear Fellow Stockholders,


I have recently returned from the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, where OXiGENE reported promising data from both our FACT trial of ZYBRESTAT in anaplastic thyroid cancer (ATC) and our FALCON trial of ZYBRESTAT in non-small cell lung cancer (NSCLC). While the detailed contents of these presentations can be found on our website (www.oxigene.com) and in the press releases we issued during the meeting, I’d like to take this opportunity to share my thoughts and feedback about OXiGENE’s experience at ASCO and our current business plans.


The FALCON poster was presented on Saturday afternoon, June 4 th , during the lung cancer session by Dr. Eddie Garon of UCLA, a well-known and respected cancer researcher. Dr. Garon generously made himself available to answer questions from what turned into a constant flow of visitors during the three-hour session. His deep expertise and commitment to patients were evident in his conversations, whether they were with physicians or members of the financial community. Many physicians appeared to be particularly intrigued by the data suggesting that the addition of ZYBRESTAT may benefit patients with a poorer performance status who are not well served by the currently approved therapies for NSCLC. The data suggesting activity in this target population are preliminary at this stage, but several attendees expressed the view that more study is warranted and that if successful, the VDA approach could be a welcome new paradigm.


Non-small cell lung cancer remains a challenging indication for OXiGENE to tackle. While we are encouraged by our data, in an earlier session at ASCO, Dr. Jean-Charles Soria from the Gustave Roussy Cancer institute in Paris raised the sobering point that over 27,000 patients have been randomized into Phase 3 trials of new targeted treatments for NSCLC between the years 2000 and 2011, but, to date, there has not been a significant improvement in survival for patients with this disease. While this statistic reminds us of the challenges facing the medical community and the drug development industry, it also clearly indicates that a new approach to treatment is required, and that the drug candidates presented at ASCO today, such as ZYBRESTAT, may be the breakthrough therapies of tomorrow.


The FACT study results were presented Monday afternoon, June 6 th , in a well attended oral presentation session on head and neck cancer. Dr. Julie Sosa, our lead investigator for the FACT study and Yale University associate professor, gave an outstanding summary of the data. We were deeply grateful for her professional, passionate presentation. The discussant was renowned thyroid cancer expert Dr. Marcia Brose from the University of Pennsylvania, who reiterated that FACT is by far the largest study ever conducted in patients with ATC, and implored the thyroid cancer community to support a follow-on study. Enthusiasm for the FACT study was a constant theme from fellow physicians at the meeting, and a representative from a major medical institution has invited investigators to present FACT data in “Grand Rounds,” which are internal educational lecture series in teaching hospitals. We look forward to continuing to share these important data, both in academic settings and at the Best of ASCO® meetings throughout the summer.


Another piece of important news that emerged during this year’s ASCO meeting was the announcement that the addition of Avastin (bevacizumab) to a chemotherapy regimen reduces the risk of progression in patients with platinum-sensitive ovarian cancer. This was of particular interest to us because OXiGENE recently announced that investigators have initiated a Phase 2 study of ZYBRESTAT in combination with bevacizumab for platinum-sensitive ovarian cancer patients. We were very encouraged to see the additional data from other studies supporting use of bevacizumab in these patients.


Finally, the OXiGENE team spent a great deal of time at ASCO meeting with potential partners for our clinical programs. The meetings were very productive, and ranged from talks with specialists interested in orphan drug marketing, to regional firms looking to enter the oncology space, to global pharmaceutical companies interested in finding a new later-phase addition to their oncology franchise. With data from two randomized controlled studies and worldwide rights available for license, we believe that ZYBRESTAT is now an asset uniquely suited for collaboration. We intend to take advantage of the interest shown in our VDA assets and continue to advance these ongoing discussions.


Overall, I believe our ASCO experience in 2011 was a great success. The data we presented and the discussions we participated in reinforced our belief that our VDA assets are backed by a substantial and growing body of data that clearly suggests their safety and activity, and that there is significant interest from potential partners. One of our tasks now is to finalize clear development plans that provide the greatest likelihood of success, not only clinically, but commercially for our later-stage assets.


Our other task is to meet our financing challenges. Realistically, our ability to press forward with later-stage development plans requires a level of resources that the company does not have today. Because we are so encouraged by current potential partner interest, and so committed to aggressively pursuing discussions based on the important data we have just presented, we intend to explore all available options for obtaining additional funds to continue to advance our clinical programs. This includes finding ways to access the capital markets as well as other sources of funding.


After a major positive experience, such as ASCO, it is appropriate to reflect on how far the company and VDA technology have come. We believe that the medical and pharmaceutical communities have become increasingly comfortable with the tolerability and combinability of vascular disrupting agents in general, and ZYBRESTAT in particular, and are eager to understand the potential applications and significance of this therapeutic approach. Despite significant advances in oncology, the number of underserved cancer patients without therapeutic options is still staggeringly high. These patients are the reason that OXiGENE is committed to advancing ZYBRESTAT and OXi4503 as potential breakthroughs in cancer therapy.


While ASCO was a major mid-year highlight, we also look forward to presenting our FACT data throughout the summer and autumn through the Best of ASCO® program, to presenting overall survival data from our FALCON study later this fall, and to providing updates on our study of OXi4503 in patients with acute myelogenous leukemia as the data become available.


As always, I am grateful for the support of our employees, patients, investigators and shareholders and I look forward to keeping everyone informed of our progress in partnering and in funding additional clinical trials.


Sincerely,
Peter J. Langecker, M.D., Ph.D.
Chief Executive Officer

byscotte

29 juin 2011 •16:40

qué passa ?

byscotte

09 juillet 2011 •07:05

http://www.dailyfinance.com/company/oxigene-inc/oxgn/nas/8-K/11960118/pdf/sec-fi lings


voila , 8 mois de trésorerie ................

Est ce suffisant pour lancement phase III zybrestat ?